| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2015-02-04 | PAT-SM6 (recombinant human monoclonal IgM antibody targeting glucose-regulated protein 78) | multiple myeloma | 1-2a | Patrys (Australia) | Cancer - Oncology |
| 2015-02-03 | Opaxio™ (paclitaxel poliglumex) | maintenance therapy in ovarian cancer |
3 | CTI Biopharma - previously known as Cell Therapeutics (USA - WA) | Cancer - Oncology |
| 2015-02-03 | F17464 | schizophrenia |
2a | Pierre Fabre Pharmaceuticals (France) | Mental diseases - CNS diseases |
| 2015-02-03 | NurOwn™ | amyotrophic lateral sclerosis (ALS) | 2 | BrainStorm Cell Therapeutics (USA - Israel) | Neurodegenerative diseases - Rare diseases |
| 2015-02-03 | ABP 501 | rheumatoid arthritis |
3 | Amgen (USA - CA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
| 2015-02-03 | PRO 140 | HIV infection |
2b | CytoDyn (Canada) | Infectious diseases |
| 2015-02-02 | human CAP® cell derived C1 Esterase Inhibitor (C1Inh) | hereditary angioedema (HAE) | preclinical | CEVEC Pharmaceuticals (Germany) | Rare diseases - Genetic diseases - Hematological diseases |
| 2015-02-02 | masitinib | nonresectable, metastatic esophagogastric adenocarcinoma | 2 | AB Science (France) | Cancer - Oncology |
| 2015-02-02 | PLX-PAD cells (Placental eXpanded cells) | muscle injury after total hip arthroplasty |
1-2 | Pluristem Therapeutics (Israel) | |
| 2015-02-01 | CGEN-15049 | preclinical | Compugen (Israel) | Cancer - Oncology | |
| 2015-01-30 | nepicastat (SYN117) | cocaine dependence |
2 | Biotie Therapies (Finland) | CNS diseases |
| 2015-01-29 | ixmyelocel-T | advanced heart failure due to ischemic dilated cardiomyopathy |
2b | Vericel (formerly Aastrom Biosciences) (USA - MA) | Cardiovascular diseases |
| 2015-01-28 | MN-001 (tipelukast) | NASH (nonalcoholic steatohepatitis) |
2 | Medicinova (USA - CA) | Liver diseases - Hepatic diseases |
| 2015-01-28 | durvalumab (MEDI4736) and tremelimumab | non-small cell lung cancer (NSCLC) | 3 | AstraZeneca (UK) | Cancer - Oncology |
| 2015-01-27 | rivaroxaban | embolic stroke of undetermined source | 3 | Bayer Healthcare (Germany) Janssen R&D, a J&J company (USA - NJ) Population Health Research Institute (PHRI) (Canada) Canadian Stroke Prevention Intervention Network (C-SPIN) (Canada) | Cardiovascular diseases |
| 2015-01-27 | Generx® (alferminogene tadenovec [Ad5FGF-4]) | stable angina pectoris | 3 | Taxus Cardium (USA - CA) | Cardiovascular diseases |
| 2015-01-27 | PF-00299804 - dacomitinib | advanced non-small cell lung cancer |
3 | Pfizer (USA - NY) | Cancer - Oncology |
| 2015-01-27 | GSK2831781 | psoriasis |
1 | GSK (UK) | Autoimmune diseases - Dermatological diseases |
| 2015-01-26 | NurOwn™ | autism | preclinical | BrainStorm Cell Therapeutics (USA - Israel) | Mental diseases - CNS diseases |
| 2015-01-23 | Azedra™ (Ultratrace® iobenguane I 131) | pheochromocytoma | 2 | Progenics Pharmaceuticals (USA - NY) | Cancer - Oncology - Rare diseases |
